B22

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
30 January 2003 (30.01.2003)

PCT

(10) International Publication Number
WO 03/008604 A2

(51) International Patent Classification[7]: C12P 13/00

(21) International Application Number: PCT/EP02/07352

(22) International Filing Date: 3 July 2002 (03.07.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
101 35 051.1 18 July 2001 (18.07.2001) DE
60/306,867 23 July 2001 (23.07.2001) US

(71) Applicant *(for all designated States except US)*: DEGUSSA AG [DE/DE]; Bennigsenplatz 1, 40474 Düsseldorf (DE).

(72) Inventor; and

(75) Inventor/Applicant *(for US only)*: HERMANN, Thomas [DE/DE]; Zirkonstrasse 8, 33739 Bielefeld (DE).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:
— *of inventorship (Rule 4.17(iv)) for US only*

[Continued on next page]

(54) Title: PROCESS FOR THE PREPARATION OF L-AMINO ACIDS USING STRAINS OF THE ENTEROBACTERIACEAE FAMILY WHICH CONTAIN AN ATTENUATED ACEB GENE



(57) Abstract: The invention relates to a process for the preparation of L-amino acids, in particular L-threonine, in which the following steps are carried out: a) fermentation of microorganisms of the Enterobacteriaceae family which produce the desired L-amino acid and in which the aceB gene, or the nucleotide sequence which codes for this, is attenuated, in particular eliminated, b) concentration of the L-amino acid in the medium or in the cells of the bacteria, and c) isolation of the L-amino acid.

WO 03/008604 A2

Published:

— *without international search report and to be republished upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Process for the Preparation of L-Amino Acids using Strains of the Enterobacteriaceae Family which Contain an Attenuated aceB Gene

Field of the Invention

This invention relates to a process for the preparation of L-amino acids, in particular L-threonine, using strains of the Enterobacteriaceae family in which the aceB gene is attenuated.

Prior Art

L-Amino acids, in particular L-threonine, are used in human medicine and in the pharmaceuticals industry, in the foodstuffs industry and very particularly in animal nutrition.

It is known to prepare L-amino acids by fermentation of strains of Enterobacteriaceae, in particular Escherichia coli (E. coli) and Serratia marcescens. Because of their great importance, work is constantly being undertaken to improve the preparation processes. Improvements to the process can relate to fermentation measures, such as e.g. stirring and supply of oxygen, or the composition of the nutrient media, such as e.g. the sugar concentration during the fermentation, or the working up to the product form, by e.g. ion exchange chromatography, or the intrinsic output properties of the microorganism itself.

Methods of mutagenesis, selection and mutant selection are used to improve the output properties of these microorganisms. Strains which are resistant to antimetabolites, such as e.g. the threonine analogue α-amino-β-hydroxyvaleric acid (AHV), or are auxotrophic for metabolites of regulatory importance and produce L-amino acid, such as e.g. L-threonine, are obtained in this manner.

Methods of the recombinant DNA technique have also been employed for some years for improving the strain of strains of the Enterobacteriaceae family which produce L-amino acids, by amplifying individual amino acid biosynthesis genes and investigating the effect on the production.

Object of the Invention

The object of the invention is to provide new measures for improved fermentative preparation of L-amino acids, in particular L-threonine.

Summary of the Invention

The invention provides a process for the fermentative preparation of L-amino acids, in particular L-threonine, using microorganisms of the Enterobacteriaceae family which in particular already produce L-amino acids and in which the nucleotide sequence which codes for the aceB gene is attenuated.

Detailed Description of the Invention

Where L-amino acids or amino acids are mentioned in the following, this means one or more amino acids, including their salts, chosen from the group consisting of L-asparagine, L-threonine, L-serine, L-glutamate, L-glycine, L-alanine, L-cysteine, L-valine, L-methionine, L-isoleucine, L-leucine, L-tyrosine, L-phenylalanine, L-histidine, L-lysine, L-tryptophan and L-arginine. L-Threonine is particularly preferred.

The term "attenuation" in this connection describes the reduction or elimination of the intracellular activity of one or more enzymes (proteins) in a microorganism which are coded by the corresponding DNA, for example by using a weak promoter or a gene or allele which codes for a corresponding enzyme with a low activity or inactivates the

corresponding enzyme (protein) or gene, and optionally combining these measures.

By attenuation measures, the activity or concentration of the corresponding protein is in general reduced to 0 to 75%, 0 to 50%, 0 to 25%, 0 to 10% or 0 to 5% of the activity or concentration of the wild-type protein or of the activity or concentration of the protein in the starting microorganism.

The process comprises carrying out the following steps:

a) fermentation of microorganisms of the Enterobacteriaceae family in which the aceB gene is attenuated,

b) concentration of the corresponding L-amino acid in the medium or in the cells of the microorganisms of the Enterobacteriaceae family, and

c) isolation of the desired L-amino acid, constituents of the fermentation broth and/or the biomass in its entirety or portions (> 0 to 100 %) thereof optionally remaining in the product.

The microorganisms which the present invention provides can produce L-amino acids from glucose, sucrose, lactose, fructose, maltose, molasses, optionally starch, optionally cellulose or from glycerol and ethanol. They are representatives of the Enterobacteriaceae family chosen from the genera Escherichia, Erwinia, Providencia and Serratia. The genera Escherichia and Serratia are preferred. Of the genus Escherichia the species Escherichia coli and of the genus Serratia the species Serratia marcescens are to be mentioned in particular.

Suitable strains, which produce L-threonine in particular, of the genus Escherichia, in particular of the species Escherichia coli, are, for example

Escherichia coli TF427
Escherichia coli H4578
Escherichia coli KY10935
Escherichia coli VNIIgenetika MG442
Escherichia coli VNIIgenetika M1
Escherichia coli VNIIgenetika 472T23
Escherichia coli BKIIM B-3996
Escherichia coli kat 13
Escherichia coli KCCM-10132

Suitable L-threonine-producing strains of the genus Serratia, in particular of the species Serratia marcescens, are, for example

Serratia marcescens HNr21
Serratia marcescens TLr156
Serratia marcescens T2000

Strains from the Enterobacteriaceae family which produce L-threonine preferably have, inter alia, one or more genetic or phenotypic features chosen from the group consisting of: resistance to α-amino-β-hydroxyvaleric acid, resistance to thialysine, resistance to ethionine, resistance to α-methylserine, resistance to diaminosuccinic acid, resistance to α-aminobutyric acid, resistance to borrelidin, resistance to rifampicin, resistance to valine analogues, such as, for example, valine hydroxamate, resistance to purine analogues, such as, for example, 6-dimethylaminopurine, a need for L-methionine, optionally a partial and compensable need for L-isoleucine, a need for meso-diaminopimelic acid, auxotrophy in respect of threonine-containing dipeptides, resistance to L-threonine, resistance to L-homoserine, resistance to L-lysine, resistance to L-methionine, resistance to L-glutamic acid, resistance to L-aspartate, resistance to L-leucine, resistance to L-phenylalanine, resistance to L-serine, resistance to L-cysteine, resistance to L-valine, sensitivity to fluoropyruvate, defective threonine

dehydrogenase, optionally an ability for sucrose utilization, enhancement of the threonine operon, enhancement of homoserine dehydrogenase I-aspartate kinase I, preferably of the feed back resistant form, enhancement of homoserine kinase, enhancement of threonine synthase, enhancement of aspartate kinase, optionally of the feed back resistant form, enhancement of aspartate semialdehyde dehydrogenase, enhancement of phosphoenol pyruvate carboxylase, optionally of the feed back resistant form, enhancement of phosphoenol pyruvate synthase, enhancement of transhydrogenase, enhancement of the RhtB gene product, enhancement of the RhtC gene product, enhancement of the YfiK gene product, enhancement of a pyruvate carboxylase, and attenuation of acetic acid formation.

It has been found that microorganisms of the Enterobacteriaceae family produce L-amino acids, in particular L-threonine, in an improved manner after attenuation, in particular elimination, of the aceB gene

The nucleotide sequences of the genes of Escherichia coli belong to the prior art and can also be found in the genome sequence of Escherichia coli published by Blattner et al. (Science 277: 1453 - 1462 (1997)).

The aceB gene is described, inter alia, by the following data:

Description:	Malate synthase A
EC No.:	4.1.3.2
Reference:	Byrne et al.; Nucleic Acids Research 16(19), 9342 (1988); Byrne et al.; Nucleic Acids Research 16(22), 10924 (1988); Cortay et al.; Biochimie 71(9-10): 1043-9 (1989)
Accession No.:	AE000474

Alternative gene name: mas

The nucleic acid sequences can be found in the databanks of the National Center for Biotechnology Information (NCBI) of the National Library of Medicine (Bethesda, MD, USA), the nucleotide sequence databank of the European Molecular Biologies Laboratories (EMBL, Heidelberg, Germany or Cambridge, UK) or the DNA databank of Japan (DDBJ, Mishima, Japan).

The genes described in the text references mentioned can be used according to the invention. Alleles of the genes which result from the degeneracy of the genetic code or due to "sense mutations" of neutral function can furthermore be used.

To achieve an attenuation, for example, expression of the gene or the catalytic properties of the enzyme proteins can be reduced or eliminated. The two measures can optionally be combined.

The reduction in gene expression can take place by suitable culturing, by genetic modification (mutation) of the signal structures of gene expression or also by the antisense-RNA technique. Signal structures of gene expression are, for example, repressor genes, activator genes, operators, promoters, attenuators, ribosome binding sites, the start codon and terminators. The expert can find information in this respect, inter alia, for example, in Jensen and Hammer (Biotechnology and Bioengineering 58: 191-195 (1998)), in Carrier and Keasling (Biotechnology Progress 15: 58-64 (1999), Franch and Gerdes (Current Opinion in Microbiology 3: 159-164 (2000)) and in known textbooks of genetics and molecular biology, such as, for example, the textbook of Knippers ("Molekulare Genetik [Molecular Genetics]", 6th edition, Georg Thieme Verlag, Stuttgart, Germany, 1995) or that of Winnacker ("Gene und Klone [Genes and Clones]", VCH Verlagsgesellschaft, Weinheim, Germany, 1990).

Mutations which lead to a change or reduction in the catalytic properties of enzyme proteins are known from the prior art. Examples which may be mentioned are the works of Qiu and Goodman (Journal of Biological Chemistry 272: 8611-8617 (1997)), Yano et al. (Proceedings of the National Academy of Sciences of the United States of America 95: 5511-5515 (1998), Wente and Schachmann (Journal of Biological Chemistry 266: 20833-20839 (1991)). Summarizing descriptions can be found in known textbooks of genetics and molecular biology, such as e.g. that by Hagemann ("Allgemeine Genetik [General Genetics]", Gustav Fischer Verlag, Stuttgart, 1986).

Possible mutations are transitions, transversions, insertions and deletions. Depending on the effect of the amino acid exchange on the enzyme activity, "missense mutations" or "nonsense mutations" are referred to. Insertions or deletions of at least one base pair in a gene lead to "frame shift mutations", which lead to incorrect amino acids being incorporated or translation being interrupted prematurely. If a stop codon is formed in the coding region as a consequence of the mutation, this also leads to a premature termination of the translation. Deletions of several codons typically lead to a complete loss of the enzyme activity. Instructions on generation of such mutations are prior art and can be found in known textbooks of genetics and molecular biology, such as e.g. the textbook by Knippers ("Molekulare Genetik [Molecular Genetics]", 6th edition, Georg Thieme Verlag, Stuttgart, Germany, 1995), that by Winnacker ("Gene und Klone [Genes and Clones]", VCH Verlagsgesellschaft, Weinheim, Germany, 1990) or that by Hagemann ("Allgemeine Genetik [General Genetics]", Gustav Fischer Verlag, Stuttgart, 1986).

Suitable mutations in the genes, such as, for example, deletion mutations, can be incorporated into suitable strains by gene or allele replacement.

A conventional method is the method, described by Hamilton et al. (Journal of Bacteriology 171: 4617-4622 (1989)), of gene replacement with the aid of a conditionally replicating pSC101 derivative pMAK705. Other methods described in the prior art, such as, for example, those of Martinez-Morales et al. (Journal of Bacteriology 181: 7143-7148 (1999)) or those of Boyd et al. (Journal of Bacteriology 182: 842-847 (2000)), can likewise be used.

It is also possible to transfer mutations in the particular genes or mutations which affect expression of the particular genes into various strains by conjugation or transduction.

It may furthermore be advantageous for the production of L-amino acids, in particular L-threonine, with strains of the Enterobacteriaceae family, in addition to attenuation of the aceB gene, for one or more enzymes of the known threonine biosynthesis pathway or enzymes of anaplerotic metabolism or enzymes for the production of reduced nicotinamide adenine dinucleotide phosphate or enzymes of glycolysis or PTS enzymes or enzymes of sulfur metabolism to be enhanced.

The term "enhancement" in this connection describes the increase in the intracellular activity of one or more enzymes or proteins in a microorganism which are coded by the corresponding DNA, for example by increasing the number of copies of the gene or genes, using a potent promoter or a gene which codes for a corresponding enzyme or protein with a high activity, and optionally combining these measures.

By enhancement measures, in particular over-expression, the activity or concentration of the corresponding protein is in general increased by at least 10%, 25%, 50%, 75%, 100%, 150%, 200%, 300%, 400% or 500%, up to a maximum of 1000% or 2000%, based on that of the wild-type protein or the

activity or concentration of the protein in the starting microorganism.

Thus, for example, at the same time one or more of the genes chosen from the group consisting of

- the thrABC operon which codes for aspartate kinase, homoserine dehydrogenase, homoserine kinase and threonine synthase (US-A-4,278,765),
- the pyc gene of Corynebacterium glutamicum which codes for pyruvate carboxylase (WO 99/18228),
- the pps gene which codes for phosphoenol pyruvate synthase (Molecular and General Genetics 231(2): 332-336 (1992)),
- the ppc gene which codes for phosphoenol pyruvate carboxylase (Gene 31: 279-283 (1984)),
- the pntA and pntB genes which code for transhydrogenase (European Journal of Biochemistry 158: 647-653 (1986)),
- the rhtB gene which imparts homoserine resistance (EP-A-0 994 190),
- the mqo gene which codes for malate:quinone oxidoreductase (WO 02/06459),
- the rhtC gene which imparts threonine resistance (EP-A-1 013 765),
- the thrE gene of Corynebacterium glutamicum which codes for the threonine export protein (WO 01/92545),
- the gdhA gene which codes for glutamate dehydrogenase (Nucleic Acids Research 11: 5257-5266 (1983); Gene 23: 199-209 (1983)),

- the hns gene which codes for the DNA-binding protein HLP-II (Molecular and General Genetics 212: 199-202 (1988)),

- the pgm gene which codes for phosphoglucomutase (Journal of Bacteriology 176: 5847-5851 (1994)),

- the fba gene which codes for fructose biphosphate aldolase (Biochemical Journal 257: 529-534 (1989)),

- the ptsH gene of the ptsHIcrr operon which codes for the phosphohistidine protein hexose phosphotransferase of the phosphotransferase system PTS (Journal of Biological Chemistry 262: 16241-16253 (1987)),

- the ptsI gene of the ptsHIcrr operon which codes for enzyme I of the phosphotransferase system PTS (Journal of Biological Chemistry 262: 16241-16253 (1987)),

- the crr gene of the ptsHIcrr operon which codes for the glucose-specific IIA component of the phosphotransferase system PTS (Journal of Biological Chemistry 262: 16241-16253 (1987)),

- the ptsG gene which codes for the glucose-specific IIBC component (Journal of Biological Chemistry 261: 16398-16403 (1986)),

- the lrp gene which codes for the regulator of the leucine regulon (Journal of Biological Chemistry 266: 10768-10774 (1991)),

- the mopB gene which codes for 10 Kd chaperone (Journal of Biological Chemistry 261: 12414-12419 (1986)) and is also known by the name groES,

- the ahpC gene of the ahpCF operon which codes for the small sub-unit of alkyl hydroperoxide reductase (Proceedings of the National Academy of Sciences of the United States of America 92: 7617-7621 (1995)),

- the ahpF gene of the ahpCF operon which codes for the large sub-unit of alkyl hydroperoxide reductase (Proceedings of the National Academy of Sciences of theUnited States of America 92: 7617-7621 (1995)),
- the cysK gene which codes for cysteine synthase A (Journal of Bacteriology 170: 3150-3157 (1988)),
- the cysB gene which codes for the regulator of the cys regulon (Journal of Biological Chemistry 262: 5999-6005 (1987)),
- the cysJ gene of the cysJIH operon which codes for the flavoprotein of NADPH sulfite reductase (Journal of Biological Chemistry 264: 15796-15808 (1989), Journal of Biological Chemistry 264: 15726-15737 (1989)),
- the cysI gene of the cysJIH operon which codes for the haemoprotein of NADPH sulfite reductase (Journal of Biological Chemistry 264: 15796-15808 (1989), Journal of Biological Chemistry 264: 15726-15737 (1989)) and
- the cysH gene of the cysJIH operon which codes for adenylyl sulfate reductase (Journal of Biological Chemistry 264: 15796-15808 (1989), Journal of Biological Chemistry 264: 15726-15737 (1989))

can be enhanced, in particular over-expressed.

The use of endogenous genes is in general preferred. "Endogenous genes" or "endogenous nucleotide sequences" are understood as meaning the genes or nucleotide sequences present in the population of a species.

It may furthermore be advantageous for the production of L-amino acids, in particular L-threonine, in addition to attenuation of the aceB gene, for one or more of the genes chosen from the group consisting of

- the tdh gene which codes for threonine dehydrogenase (Journal of Bacteriology 169: 4716-4721 (1987)),
- the mdh gene which codes for malate dehydrogenase (E.C. 1.1.1.37) (Archives in Microbiology 149: 36-42 (1987)),
- the gene product of the open reading frame (orf) yjfA (Accession Number AAC77180 of the National Center for Biotechnology Information (NCBI, Bethesda, MD, USA)),
- the gene product of the open reading frame (orf) ytfP (Accession Number AAC77179 of the National Center for Biotechnology Information (NCBI, Bethesda, MD, USA)),
- the pckA gene which codes for the enzyme phosphoenol pyruvate carboxykinase (Journal of Bacteriology 172: 7151-7156 (1990)),
- the poxB gene which codes for pyruvate oxidase (Nucleic Acids Research 14(13): 5449-5460 (1986)),
- the aceA gene which codes for the enzyme isocitrate lyase (Journal of Bacteriology 170: 4528-4536 (1988)),
- the dgsA gene which codes for the DgsA regulator of the phosphotransferase system (Bioscience, Biotechnology and Biochemistry 59: 256-261 (1995)) and is also known under the name of the mlc gene,
- the fruR gene which codes for the fructose repressor (Molecular and General Genetics 226: 332-336 (1991)) and is also known under the name of the cra gene,
- the rpoS gene which codes for the sigma^{38} factor (WO 01/05939) and is also known under the name of the katF gene,
- the aspA gene which codes for aspartate ammonium lyase (Nucleic Acids Research 13(6): 2063-2074 (1985)),

- the aceK gene which codes for isocitrate dehydrogenase kinase/phosphatase (Journal of Bacteriology 170(1): 89-97 (1988)) and

- the ugpB gene which codes for the periplasmic binding protein of the sn-glycerol 3-phosphate transport system (Molecular Microbiology 2(6): 767-775 (1988))

to be attenuated, in particular eliminated or for the expression thereof to be reduced.

It may furthermore be advantageous for the production of L-amino acids, in particular L-threonine, in addition to attenuation of the aceB gene, to eliminate undesirable side reactions (Nakayama: "Breeding of Amino Acid Producing Microorganisms", in: Overproduction of Microbial Products, Krumphanzl, Sikyta, Vanek (eds.), Academic Press, London, UK, 1982).

The microorganisms produced according to the invention can be cultured in the batch process (batch culture), the fed batch process (feed process) or the repeated fed batch process (repetitive feed process). A summary of known culture methods is described in the textbook by Chmiel (Bioprozesstechnik 1. Einführung in die Bioverfahrenstechnik [Bioprocess Technology 1. Introduction to Bioprocess Technology (Gustav Fischer Verlag, Stuttgart, 1991)) or in the textbook by Storhas (Bioreaktoren und periphere Einrichtungen [Bioreactors and Peripheral Equipment] (Vieweg Verlag, Braunschweig/Wiesbaden, 1994)).

The culture medium to be used must meet the requirements of the particular strains in a suitable manner. Descriptions of culture media for various microorganisms are contained in the handbook "Manual of Methods for General Bacteriology" of the American Society for Bacteriology (Washington D.C., USA, 1981).

Sugars and carbohydrates, such as e.g. glucose, sucrose, lactose, fructose, maltose, molasses, starch and optionally cellulose, oils and fats, such as e.g. soya oil, sunflower oil, groundnut oil and coconut fat, fatty acids, such as e.g. palmitic acid, stearic acid and linoleic acid, alcohols, such as e.g. glycerol and ethanol, and organic acids, such as e.g. acetic acid, can be used as the source of carbon. These substances can be used individually or as a mixture.

Organic nitrogen-containing compounds, such as peptones, yeast extract, meat extract, malt extract, corn steep liquor, soya bean flour and urea, or inorganic compounds, such as ammonium sulfate, ammonium chloride, ammonium phosphate, ammonium carbonate and ammonium nitrate, can be used as the source of nitrogen. The sources of nitrogen can be used individually or as a mixture.

Phosphoric acid, potassium dihydrogen phosphate or dipotassium hydrogen phosphate or the corresponding sodium-containing salts can be used as the source of phosphorus. The culture medium must furthermore comprise salts of metals, such as e.g. magnesium sulfate or iron sulfate, which are necessary for growth. Finally, essential growth substances, such as amino acids and vitamins, can be employed in addition to the abovementioned substances. Suitable precursors can moreover be added to the culture medium. The starting substances mentioned can be added to the culture in the form of a single batch, or can be fed in during the culture in a suitable manner.

Basic compounds, such as sodium hydroxide, potassium hydroxide, ammonia or aqueous ammonia, or acid compounds, such as phosphoric acid or sulfuric acid, can be employed in a suitable manner to control the pH of the culture. Antifoams, such as e.g. fatty acid polyglycol esters, can be employed to control the development of foam. Suitable substances having a selective action, e.g. antibiotics, can

be added to the medium to maintain the stability of plasmids. To maintain aerobic conditions, oxygen or oxygen-containing gas mixtures, such as e.g. air, are introduced into the culture. The temperature of the culture is usually 25ºC to 45ºC, and preferably 30ºC to 40ºC. Culturing is continued until a maximum of L-amino acids or L-threonine has formed. This target is usually reached within 10 hours to 160 hours.

The analysis of L-amino acids can be carried out by anion exchange chromatography with subsequent ninhydrin derivation, as described by Spackman et al. (Analytical Chemistry 30: 1190-1206 (1958)), or it can take place by reversed phase HPLC as described by Lindroth et al. (Analytical Chemistry 51: 1167-1174 (1979)).

The process according to the invention is used for the fermentative preparation of L-amino acids, such as, for example, L-threonine, L-isoleucine, L-valine, L-methionine, L-homoserine and L-lysine, in particular L-threonine.

A pure culture of the Escherichia coli K-12 strain DH5α/pMAK705 was deposited as DSM 13720 on 8th September 2000 at the Deutsche Sammlung für Mikroorganismen und Zellkulturen (DSMZ = German Collection of Microorganisms and Cell Cultures, Braunschweig, Germany) in accordance with the Budapest Treaty.

The present invention is explained in more detail in the following with the aid of embodiment examples.

The isolation of plasmid DNA from Escherichia coli and all techniques of restriction, ligation, Klenow and alkaline phosphatase treatment are carried out by the method of Sambrook et al. (Molecular Cloning - A Laboratory Manual (1989) Cold Spring Harbor Laboratory Press). Unless described otherwise, the transformation of Escherichia coli is carried out by the method of Chung et al. (Proceedings

of the National Academy of Sciences of the United States of America 86: 2172-2175 (1989)).

The incubation temperature for the preparation of strains and transformants is 37ºC. Temperatures of 30ºC and 44ºC are used in the gene replacement method of Hamilton et al.

Example 1

Construction of the deletion mutation of the aceB gene

Parts of the gene regions lying upstream and downstream of the aceB gene and parts of the 5' and 3' region of the aceB gene are amplified from Escherichia coli K12 using the polymerase chain reaction (PCR) and synthetic oligonucleotides. Starting from the nucleotide sequence of the aceB gene and sequences lying upstream and downstream in E. coli K12 MG1655 (SEQ ID No. 1, Accession Number AE000474), the following PCR primers are synthesized (MWG Biotech, Ebersberg, Germany):

aceB5'-1: 5' - TTCGGATCCATGACGAGGAG - 3' (SEQ ID No. 3)

aceB5'-2: 5' - TTGCCAACAGTGCCTGATAG - 3' (SEQ ID No. 4)

aceB3'-1: 5' - ATGCTTACTCACGCCTGTTG - 3' (SEQ ID No. 5)

aceB3'-2: 5' - CATGTGCAGATGCTCCATAG - 3' (SEQ ID No. 6)

The chromosomal E. coli K12 MG1655 DNA employed for the PCR is isolated according to the manufacturer's instructions with "Qiagen Genomic-tips 100/G" (QIAGEN, Hilden, Germany). A DNA fragment approx. 650 bp in size from the 5' region of the aceB gene region (called aceB5') and a DNA fragment approx. 700 bp in size from the 3' region of the aceB gene region (called aceB3') can be amplified with the specific primers under standard PCR conditions (Innis et al. (1990) PCR Protocols. A Guide to Methods and Applications, Academic Press) with Taq-DNA polymerase (Gibco-BRL, Eggenstein, Germany). The PCR products are each ligated

with the vector pCRII-TOPO (TOPO TA Cloning Kit, Invitrogen, Groningen, The Netherlands) in accordance with the manufacturer's instructions and transformed into the E. coli strain TOP10F'. Selection of plasmid-carrying cells takes place on LB agar, to which 50 µg/ml ampicillin are added. After isolation of the plasmid DNA, the vector pCRII-TOPOaceB3' is cleaved with the restriction enzymes XbaI and Ecl136II. The aceB5' fragment is isolated after separation in 0.8% agarose gel with the aid of the QIAquick Gel Extraction Kit (QIAGEN, Hilden, Germany). After isolation of the plasmid DNA the vector pCRII-TOPOaceB5' is cleaved with the enzymes EcoRV and XbaI and ligated with the aceB5' fragment isolated. The E. coli strain DH5α is transformed with the ligation batch and plasmid-carrying cells are selected on LB agar, to which 50 µg/ml ampicillin are added. After isolation of the plasmid DNA those plasmids in which the mutagenic DNA sequence shown in SEQ ID No. 7 is cloned are detected by control cleavage with the enzymes BclI, HincII, SpeI and SphI. One of the plasmids is called pCRII-TOPOΔaceB (=pCRII-TOPOdeltaaceB).

Example 2

Construction of the replacement vector pMAK705ΔaceB

The ΔaceB allele described in example 1 is isolated from the vector pCRII-TOPOΔaceB after restriction with the enzymes KpnI and XbaI and separation in 0.8% agarose gel, and ligated with the plasmid pMAK705 (Hamilton et al., Journal of Bacteriology 171: 4617-4622 (1989)), which has been digested with the enzymes KpnI and XbaI. The ligation batch is transformed in DH5α and plasmid-carrying cells are selected on LB agar, to which 20 µg/ml chloramphenicol are added. Successful cloning is demonstrated after isolation of the plasmid DNA and cleavage with the enzymes BamHI, ClaI, PauI and XbaI. The replacement vector formed, pMAK705ΔaceB (= pMAK705deltaaceB), is shown in Figure 1.

Example 3

Position-specific mutagenesis of the aceB gene in the E. coli strain MG442

The L-threonine-producing E. coli strain MG442 is described in the patent specification US-A- 4,278,765 and deposited as CMIM B-1628 at the Russian National Collection for Industrial Microorganisms (VKPM, Moscow, Russia).

For replacement of the chromosomal aceB gene with the plasmid-coded deletion construct, MG442 is transformed with the plasmid pMAK705ΔaceB. The gene replacement is carried out using the selection method described by Hamilton et al. (Journal of Bacteriology 171: 4617-4622 (1989)) and is verified by standard PCR methods (Innis et al. (1990) PCR Protocols. A Guide to Methods and Applications, Academic Press) with the following oligonucleotide primers:

aceB5'-1: 5' - TTCGGATCCATGACGAGGAG - 3' (SEQ ID No. 3)

aceB3'-2: 5' - CATGTGCAGATGCTCCATAG - 3' (SEQ ID No. 6)

After replacement has taken place, MG442 contains the form of the ΔaceB allele shown in SEQ ID No. 8. The strain obtained is called MG442ΔaceB.

Example 4

Preparation of L-threonine with the strain MG442ΔaceB

MG442ΔaceB is multiplied on minimal medium with the following composition: 3.5 g/l $Na_2HPO_4*2H_2O$, 1.5 g/l KH_2PO_4, 1 g/l NH_4Cl, 0.1 g/l $MgSO_4*7H_2O$, 2 g/l glucose, 20 g/l agar. The formation of L-threonine is checked in batch cultures of 10 ml contained in 100 ml conical flasks. For this, 10 ml of preculture medium of the following composition: 2 g/l yeast extract, 10 g/l $(NH_4)_2SO_4$, 1 g/l KH_2PO_4, 0.5 g/l $MgSO_4*7H_2O$, 15 g/l $CaCO_3$, 20 g/l glucose are inoculated and the batch is incubated for 16 hours at 37°C and 180 rpm on

an ESR incubator from Kühner AG (Birsfelden, Switzerland). 250 µl of this preculture are transinoculated into 10 ml of production medium (25 g/l $(NH_4)_2SO_4$, 2 g/l KH_2PO_4, 1 g/l $MgSO_4*7H_2O$, 0.03 g/l $FeSO_4*7H_2O$, 0.018 g/l $MnSO_4*1H_2O$, 30 g/l $CaCO_3$, 20 g/l glucose) and the batch is incubated for 48 hours at 37ºC. After the incubation the optical density (OD) of the culture suspension is determined with an LP2W photometer from Dr. Lange (Düsseldorf, Germany) at a measurement wavelength of 660 nm.

The concentration of L-threonine formed is then determined in the sterile-filtered culture supernatant with an amino acid analyzer from Eppendorf-BioTronik (Hamburg, Germany) by ion exchange chromatography and post-column reaction with ninhydrin detection.

The result of the experiment is shown in Table 1.

Table 1

Strain	OD (660 nm)	L-Threonine g/l
MG442	6.0	1.5
MG442ΔaceB	4.8	2.1

Brief Description of the Figure:

- Figure 1: pMAK705ΔaceB (= pMAK705deltaaceB)

The length data are to be understood as approx. data. The abbreviations and designations used have the following meaning:

- cat: Chloramphenicol resistance gene
- rep-ts: Temperature-sensitive replication region of the plasmid pSC101

- aceB5': Part of the 5' region of the aceB gene and the region lying upstream
- aceB3': Part of the 3' region of the aceB gene and the region lying downstream

The abbreviations for the restriction enzymes have the following meaning

- BamHI: Restriction endonuclease from Bacillus amyloliquefaciens H
- ClaI: Restriction endonuclease from Caryphanon latum
- KpnI: Restriction endonuclease from Klebsiella pneumoniae
- PauI: Restriction endonuclease from Paracoccus alcaliphilus
- XbaI: Restriction endonuclease from Xanthomonas badrii

What is claimed is:

1. A process for the preparation of L-amino acids, in particular L-threonine, which comprises carrying out the following steps:

   a) fermentation of microorganisms of the Enterobacteriaceae family which produce the desired L-amino acid and in which the aceB gene, or the nucleotide sequence which codes for this, is attenuated, in particular eliminated,

   b) concentration of the desired L-amino acid in the medium or in the cells of the microorganisms, and

   c) isolation of the desired L-amino acid, constituents of the fermentation broth and/or the biomass in its entirety or portions (> 0 to 100 %) thereof optionally remaining in the product.

2. A process as claimed in claim 1, wherein microorganisms in which further genes of the biosynthesis pathway of the desired L-amino acid are additionally enhanced are employed.

3. A process as claimed in claim 1, wherein microorganisms in which the metabolic pathways which reduce the formation of the desired L-amino acid are at least partly eliminated are employed.

4. A process as claimed in claim 1, wherein the expression of the polynucleotide which codes for the aceB gene is attenuated, in particular eliminated.

5. A process as claimed in claim 1, wherein the regulatory and/or catalytic properties of the polypeptide (enzyme protein) for which the polynucleotide aceB codes are reduced.

6. A process as claimed in claim 1, wherein, for the preparation of L-amino acids, microorganisms of the Enterobacteriaceae family in which in addition at the same time one or more of the genes chosen from the group consisting of:

6.1 the thrABC operon which codes for aspartate kinase, homoserine dehydrogenase, homoserine kinase and threonine synthase,

6.2 the pyc gene which codes for pyruvate carboxylase,

6.3 the pps gene which codes for phosphoenol pyruvate synthase,

6.4 the ppc gene which codes for phosphoenol pyruvate carboxylase,

6.5 the pntA and pntB genes which code for transhydrogenase,

6.6 the rhtB gene which imparts homoserine resistance,

6.7 the mqo gene which codes for malate:quinone oxidoreductase,

6.8 the rhtC gene which imparts threonine resistance,

6.9 the thrE gene which codes for the threonine export protein,

6.10 the gdhA gene which codes for glutamate dehydrogenase,

6.11 the hns gene which codes for the DNA-binding protein HLP-II,

6.12 the pgm gene which codes for phosphoglucomutase,

6.13 the fba gene which codes for fructose biphosphate aldolase,

6.14 the ptsH gene which codes for the phosphohistidine protein hexose phosphotransferase,

6.15 the ptsI gene which codes for enzyme I of the phosphotransferase system,

6.16 the crr gene which codes for the glucose-specific IIA component,

6.17 the ptsG gene which codes for the glucose-specific IIBC component,

6.18 the lrp gene which codes for the regulator of the leucine regulon,

6.19 the mopB gene which codes for 10 Kd chaperone,

6.20 the ahpC gene which codes for the small sub-unit of alkyl hydroperoxide reductase,

6.21 the ahpF gene which codes for the large sub-unit of alkyl hydroperoxide reductase,

6.22 the cysK gene which codes for cysteine synthase A,

6.23 the cysB gene which codes for the regulator of the cys regulon,

6.24 the cysJ gene which codes for the flavoprotein of NADPH sulfite reductase,

6.25 the cysI gene which codes for the haemoprotein of NADPH sulfite reductase and

6.26 the cysH gene which codes for adenylyl sulfate reductase,

is or are enhanced, in particular over-expressed, are fermented.

7. A process as claimed in claim 1, wherein, for the preparation of L-amino acids, microorganisms of the Enterobacteriaceae family in which in addition at the same time one or more of the genes chosen from the group consisting of:

7.1 the tdh gene which codes for threonine dehydrogenase,

7.2 the mdh gene which codes for malate dehydrogenase,

7.3 the gene product of the open reading frame (orf) yjfA,

7.4 the gene product of the open reading frame (orf) ytfP,

7.5 the pckA gene which codes for phosphoenol pyruvate carboxykinase

7.6 the poxB gene which codes for pyruvate oxidase

7.7 the aceA gene which codes for isocitrate lyase,

7.8 the dgsA gene which codes for the DgsA regulator of the phosphotransferase system,

7.9 the fruR gene which codes for the fructose repressor,

7.10 the rpoS gene which codes for the sigma^{38} factor,

7.11 the aspA gene which codes for aspartate ammonium lyase,

7.12 the aceK gene which codes for isocitrate dehydrogenase kinase/phosphatase and

7.13 the ugpB gene which codes for the periplasmic binding protein of the sn-glycerol 3-phosphate transport system

is or are attenuated, in particular eliminated or reduced in expression, are fermented.

Figure 1:


PauI
cat
rep-
pMAK705deltaaceB
7105 bps
ClaI
KpnI
BamH
aceB3
BamH
PauI
aceB5
BamH
XbaI
BamH
PauI

SEQUENCE PROTOCOL

<110> Degussa AG

<120> Process for the preparation of L-amino acids using strains of the Enterobacteriaceae family which contain an attenuated aceB gene

<130> 020271 BT

<160> 8

<170> PatentIn version 3.1

<210> 1
<211> 1661
<212> DNA
<213> Escherichia coli

<220>
<221> CDS
<222> (28)..(1629)
<223> aceB gene.

<400> 1

```
ttcggatcca tgacgaggag ctgcacg atg act gaa cag gca aca aca acc gat      54
                              Met Thr Glu Gln Ala Thr Thr Thr Asp
                              1               5

gaa ctg gct ttc aca agg ccg tat ggc gag cag gag aag caa att ctt      102
Glu Leu Ala Phe Thr Arg Pro Tyr Gly Glu Gln Glu Lys Gln Ile Leu
10                  15                  20                  25

act gcc gaa gcg gta gaa ttt ctg act gag ctg gtg acg cat ttt acg      150
Thr Ala Glu Ala Val Glu Phe Leu Thr Glu Leu Val Thr His Phe Thr
            30                  35                  40

cca caa cgc aat aaa ctt ctg gca gcg cgc att cag cag cag caa gat      198
Pro Gln Arg Asn Lys Leu Leu Ala Ala Arg Ile Gln Gln Gln Gln Asp
        45                  50                  55

att gat aac gga acg ttg cct gat ttt att tcg gaa aca gct tcc att      246
Ile Asp Asn Gly Thr Leu Pro Asp Phe Ile Ser Glu Thr Ala Ser Ile
    60                  65                  70

cgc gat gct gat tgg aaa att cgc ggg att cct gcg gac tta gaa gac      294
Arg Asp Ala Asp Trp Lys Ile Arg Gly Ile Pro Ala Asp Leu Glu Asp
75                  80                  85

cgc cgc gta gag ata act ggc ccg gta gag cgc aag atg gtg atc aac      342
Arg Arg Val Glu Ile Thr Gly Pro Val Glu Arg Lys Met Val Ile Asn
90                  95                  100                 105

gcg ctc aac gcc aat gtg aaa gtc ttt atg gcc gat ttc gaa gat tca      390
Ala Leu Asn Ala Asn Val Lys Val Phe Met Ala Asp Phe Glu Asp Ser
            110                 115                 120

ctg gca cca gac tgg aac aaa gtg atc gac ggg caa att aac ctg cgt      438
Leu Ala Pro Asp Trp Asn Lys Val Ile Asp Gly Gln Ile Asn Leu Arg
        125                 130                 135

gat gcg gtt aac ggc acc atc agt tac acc aat gaa gca ggc aaa att      486
Asp Ala Val Asn Gly Thr Ile Ser Tyr Thr Asn Glu Ala Gly Lys Ile
    140                 145                 150
```

```
tac cag ctc aag ccc aat cca gcg gtt ttg att tgt cgg gta cgc ggt      534
Tyr Gln Leu Lys Pro Asn Pro Ala Val Leu Ile Cys Arg Val Arg Gly
    155                 160                 165

ctg cac ttg ccg gaa aaa cat gtc acc tgg cgt ggt gag gca atc ccc      582
Leu His Leu Pro Glu Lys His Val Thr Trp Arg Gly Glu Ala Ile Pro
170                 175                 180                 185

ggc agc ctg ttt gat ttt gcg ctc tat ttc ttc cac aac tat cag gca      630
Gly Ser Leu Phe Asp Phe Ala Leu Tyr Phe Phe His Asn Tyr Gln Ala
                190                 195                 200

ctg ttg gca aag ggc agt ggt ccc tat ttc tat ctg ccg aaa acc cag      678
Leu Leu Ala Lys Gly Ser Gly Pro Tyr Phe Tyr Leu Pro Lys Thr Gln
            205                 210                 215

tcc tgg cag gaa gcg gcc tgg tgg agc gaa gtc ttc agc tat gca gaa      726
Ser Trp Gln Glu Ala Ala Trp Trp Ser Glu Val Phe Ser Tyr Ala Glu
        220                 225                 230

gat cgc ttt aat ctg ccg cgc ggc acc atc aag gcg acg ttg ctg att      774
Asp Arg Phe Asn Leu Pro Arg Gly Thr Ile Lys Ala Thr Leu Leu Ile
    235                 240                 245

gaa acg ctg ccc gcc gtg ttc cag atg gat gaa atc ctt cac gcg ctg      822
Glu Thr Leu Pro Ala Val Phe Gln Met Asp Glu Ile Leu His Ala Leu
250                 255                 260                 265

cgt gac cat att gtt ggt ctg aac tgc ggt cgt tgg gat tac atc ttc      870
Arg Asp His Ile Val Gly Leu Asn Cys Gly Arg Trp Asp Tyr Ile Phe
                270                 275                 280

agc tat atc aaa acg ttg aaa aac tat ccc gat cgc gtc ctg cca gac      918
Ser Tyr Ile Lys Thr Leu Lys Asn Tyr Pro Asp Arg Val Leu Pro Asp
            285                 290                 295

aga cag gca gtg acg atg gat aaa cca ttc ctg aat gct tac tca cgc      966
Arg Gln Ala Val Thr Met Asp Lys Pro Phe Leu Asn Ala Tyr Ser Arg
        300                 305                 310

ctg ttg att aaa acc tgc cat aaa cgc ggt gct ttt gcg atg ggc ggc     1014
Leu Leu Ile Lys Thr Cys His Lys Arg Gly Ala Phe Ala Met Gly Gly
    315                 320                 325

atg gcg gcg ttt att ccg agc aaa gat gaa gag cac aat aac cag gtg     1062
Met Ala Ala Phe Ile Pro Ser Lys Asp Glu Glu His Asn Asn Gln Val
330                 335                 340                 345

ctc aac aaa gta aaa gcg gat aaa tcg ctg gaa gcc aat aac ggt cac     1110
Leu Asn Lys Val Lys Ala Asp Lys Ser Leu Glu Ala Asn Asn Gly His
                350                 355                 360

gat ggc aca tgg atc gct cac cca ggc ctt gcg gac acg gca atg gcg     1158
Asp Gly Thr Trp Ile Ala His Pro Gly Leu Ala Asp Thr Ala Met Ala
            365                 370                 375

gta ttc aac gac att ctc ggc tcc cgt aaa aat cag ctt gaa gtg atg     1206
Val Phe Asn Asp Ile Leu Gly Ser Arg Lys Asn Gln Leu Glu Val Met
        380                 385                 390

cgc gaa caa gac gcg ccg att act gcc gat cag ctg ctg gca cct tgt     1254
Arg Glu Gln Asp Ala Pro Ile Thr Ala Asp Gln Leu Leu Ala Pro Cys
    395                 400                 405
```

```
gat ggt gaa cgc acc gaa gaa ggt atg cgc gcc aac att cgc gtg gct     1302
Asp Gly Glu Arg Thr Glu Glu Gly Met Arg Ala Asn Ile Arg Val Ala
410                 415                 420                 425

gtg cag tac atc gaa gcg tgg atc tct ggc aac ggc tgt gtg ccg att     1350
Val Gln Tyr Ile Glu Ala Trp Ile Ser Gly Asn Gly Cys Val Pro Ile
                430                 435                 440

tat ggc ctg atg gaa gat gcg gcg acg gct gaa att tcc cgt acc tcg     1398
Tyr Gly Leu Met Glu Asp Ala Ala Thr Ala Glu Ile Ser Arg Thr Ser
            445                 450                 455

atc tgg cag tgg atc cat cat caa aaa acg ttg agc aat ggc aaa ccg     1446
Ile Trp Gln Trp Ile His His Gln Lys Thr Leu Ser Asn Gly Lys Pro
        460                 465                 470

gtg acc aaa gcc ttg ttc cgc cag atg ctg ggc gaa gag atg aaa gtc     1494
Val Thr Lys Ala Leu Phe Arg Gln Met Leu Gly Glu Glu Met Lys Val
    475                 480                 485

att gcc agc gaa ctg ggc gaa gaa cgt ttc tcc cag ggg cgt ttt gac     1542
Ile Ala Ser Glu Leu Gly Glu Glu Arg Phe Ser Gln Gly Arg Phe Asp
490                 495                 500                 505

gat gcc gca cgc ttg atg gaa cag atc acc act tcc gat gag tta att     1590
Asp Ala Ala Arg Leu Met Glu Gln Ile Thr Thr Ser Asp Glu Leu Ile
                510                 515                 520

gat ttc ctg acc ctg cca ggc tac cgc ctg tta gcg taa accaccacat     1639
Asp Phe Leu Thr Leu Pro Gly Tyr Arg Leu Leu Ala
            525                 530

aactatggag catctgcaca tg                                          1661
```

<210> 2
<211> 533
<212> PRT
<213> Escherichia coli

<400> 2

```
Met Thr Glu Gln Ala Thr Thr Thr Asp Glu Leu Ala Phe Thr Arg Pro
1               5                   10                  15

Tyr Gly Glu Gln Glu Lys Gln Ile Leu Thr Ala Glu Ala Val Glu Phe
            20                  25                  30

Leu Thr Glu Leu Val Thr His Phe Thr Pro Gln Arg Asn Lys Leu Leu
        35                  40                  45

Ala Ala Arg Ile Gln Gln Gln Gln Asp Ile Asp Asn Gly Thr Leu Pro
    50                  55                  60

Asp Phe Ile Ser Glu Thr Ala Ser Ile Arg Asp Ala Asp Trp Lys Ile
65                  70                  75                  80

Arg Gly Ile Pro Ala Asp Leu Glu Asp Arg Arg Val Glu Ile Thr Gly
                85                  90                  95

Pro Val Glu Arg Lys Met Val Ile Asn Ala Leu Asn Ala Asn Val Lys
            100                 105                 110

Val Phe Met Ala Asp Phe Glu Asp Ser Leu Ala Pro Asp Trp Asn Lys
        115                 120                 125
```

Val Ile Asp Gly Gln Ile Asn Leu Arg Asp Ala Val Asn Gly Thr Ile
130 135 140

Ser Tyr Thr Asn Glu Ala Gly Lys Ile Tyr Gln Leu Lys Pro Asn Pro
145 150 155 160

Ala Val Leu Ile Cys Arg Val Arg Gly Leu His Leu Pro Glu Lys His
165 170 175

Val Thr Trp Arg Gly Glu Ala Ile Pro Gly Ser Leu Phe Asp Phe Ala
180 185 190

Leu Tyr Phe Phe His Asn Tyr Gln Ala Leu Leu Ala Lys Gly Ser Gly
195 200 205

Pro Tyr Phe Tyr Leu Pro Lys Thr Gln Ser Trp Gln Glu Ala Ala Trp
210 215 220

Trp Ser Glu Val Phe Ser Tyr Ala Glu Asp Arg Phe Asn Leu Pro Arg
225 230 235 240

Gly Thr Ile Lys Ala Thr Leu Leu Ile Glu Thr Leu Pro Ala Val Phe
245 250 255

Gln Met Asp Glu Ile Leu His Ala Leu Arg Asp His Ile Val Gly Leu
260 265 270

Asn Cys Gly Arg Trp Asp Tyr Ile Phe Ser Tyr Ile Lys Thr Leu Lys
275 280 285

Asn Tyr Pro Asp Arg Val Leu Pro Asp Arg Gln Ala Val Thr Met Asp
290 295 300

Lys Pro Phe Leu Asn Ala Tyr Ser Arg Leu Leu Ile Lys Thr Cys His
305 310 315 320

Lys Arg Gly Ala Phe Ala Met Gly Gly Met Ala Ala Phe Ile Pro Ser
325 330 335

Lys Asp Glu Glu His Asn Asn Gln Val Leu Asn Lys Val Lys Ala Asp
340 345 350

Lys Ser Leu Glu Ala Asn Asn Gly His Asp Gly Thr Trp Ile Ala His
355 360 365

Pro Gly Leu Ala Asp Thr Ala Met Ala Val Phe Asn Asp Ile Leu Gly
370 375 380

Ser Arg Lys Asn Gln Leu Glu Val Met Arg Glu Gln Asp Ala Pro Ile
385 390 395 400

Thr Ala Asp Gln Leu Leu Ala Pro Cys Asp Gly Glu Arg Thr Glu Glu
405 410 415

Gly Met Arg Ala Asn Ile Arg Val Ala Val Gln Tyr Ile Glu Ala Trp
420 425 430

Ile Ser Gly Asn Gly Cys Val Pro Ile Tyr Gly Leu Met Glu Asp Ala
435 440 445

Ala Thr Ala Glu Ile Ser Arg Thr Ser Ile Trp Gln Trp Ile His His
450 455 460

Gln Lys Thr Leu Ser Asn Gly Lys Pro Val Thr Lys Ala Leu Phe Arg
465 470 475 480

Gln Met Leu Gly Glu Glu Met Lys Val Ile Ala Ser Glu Leu Gly Glu
485 490 495

Glu Arg Phe Ser Gln Gly Arg Phe Asp Asp Ala Ala Arg Leu Met Glu
500 505 510

Gln Ile Thr Thr Ser Asp Glu Leu Ile Asp Phe Leu Thr Leu Pro Gly
515 520 525

Tyr Arg Leu Leu Ala
530

<210> 3
<211> 20
<212> DNA
<213> artificial sequence

<220>
<221> Primer
<222> (1)..(20)
<223> aceB5'-1

<400> 3
ttcggatcca tgacgaggag 20

<210> 4
<211> 20
<212> DNA
<213> artificial sequence

<220>
<221> Primer
<222> (1)..(20)
<223> aceB5'-2

<400> 4
ttgccaacag tgcctgatag 20

<210> 5
<211> 20
<212> DNA
<213> artificial sequence

<220>
<221> Primer
<222> (1)..(20)
<223> aceB3'-1

<400> 5
atgcttactc acgcctgttg 20

<210> 6
<211> 20
<212> DNA
<213> artificial sequence

<220>
<221> Primer
<222> (1)..(20)
<223> aceB3'-2

<400> 6
catgtgcaga tgctccatag 20

<210> 7
<211> 1520
<212> DNA
<213> Escherichia coli

<220>
<221> misc_feature
<222> (1)..(1520)
<223> mutagenic DNA

<220>
<221> misc_feature
<222> (1)..(55)
<223> technical DNA / residues of polylinker sequence

<220>
<221> misc_feature
<222> (56)..(695)
<223> parts of the 5' region of the aceB gene and regions lying upstream

<220>
<221> misc_feature
<222> (696)..(758)
<223> technical DNA / residues of polylinker sequence

<220>
<221> misc_feature
<222> (759)..(1467)
<223> parts of the 3' region of the aceB gene and regions lying downstream

<220>
<221> misc_feature
<222> (1468)..(1520)
<223> technical DNA / residues of polylinker sequence

<400> 7
ctagatgcat gctcgagcgg ccgccagtgt gatggatatc tgcagaattc ggcttttcgg 60

atccatgacg aggagctgca cgatgactga acaggcaaca acaaccgatg aactggcttt 120

cacaaggccg tatggcgagc aggagaagca aattcttact gccgaagcgg tagaatttct 180

gactgagctg gtgacgcatt ttacgccaca acgcaataaa cttctggcag cgcgcattca 240

gcagcagcaa gatattgata acggaacgtt gcctgatttt atttcggaaa cagcttccat 300

tcgcgatgct gattggaaaa ttcgcgggat tcctgcggac ttagaagacc gccgcgtaga 360

gataactggc ccggtagagc gcaagatggt gatcaacgcg ctcaacgcca atgtgaaagt 420

ctttatggcc gatttcgaag attcactggc accagactgg aacaaagtga tcgacgggca 480

aattaacctg cgtgatgcgg ttaacggcac catcagttac accaatgaag caggcaaaat 540

ttaccagctc aagcccaatc cagcggtttt gatttgtcgg gtacgcggtc tgcacttgcc 600

ggaaaaacat gtcacctggc gtggtgaggc aatccccggc agcctgtttg attttgcgct 660

ctatttcttc cacaactatc aggcactgtt ggcaaaagcc gaattccagc acactggcgg 720

ccgttactag tggatccgag atctgcagaa ttcggcttat gcttactcac gcctgttgat 780

[illegible] 840

caaagatgaa gagcacaata accaggtgct caacaaagta aaagcggata aatcgctgga 900

agccaataac ggtcacgatg gcacatggat cgctcaccca ggccttgcgg acacggcaat 960

ggcggtattc aacgacattc tcggctcccg taaaaatcag cttgaagtga tgcgcgaaca 1020

agacgcgccg attactgccg atcagctgct ggcaccttgt gatggtgaac gcaccgaaga 1080

aggtatgcgc gccaacattc gcgtggctgt gcagtacatc gaagcgtgga tctctggcaa 1140

cggctgtgtg ccgatttatg gcctgatgga agatgcggcg acggctgaaa tttcccgtac 1200

ctcgatctgg cagtggatcc atcatcaaaa aacgttgagc aatggcaaac cggtgaccaa 1260

agccttgttc cgccagatgc tgggcgaaga gatgaaagtc attgccagcg aactgggcga 1320

agaacgtttc tcccaggggc gttttgacga tgccgcacgc ttgatggaac agatcaccac 1380

ttccgatgag ttaattgatt tcctgaccct gccaggctac cgcctgttag cgtaaaccac 1440

cacataacta tggagcatct gcacatgaag ccgaattcca gcacactggc ggccgttact 1500

agtggatccg agctcggtac 1520

<210> 8
<211> 1353
<212> DNA
<213> Escherichia coli

<220>
<221> misc_feature
<222> (1)..(1353)
<223> mutagenic DNA

<220>
<221> misc_feature
<222> (1)..(3)
<223> start codon of the deltaaceB allele

<220>
<221> misc_feature
<222> (1)..(613)
<223> 5' region of the deltaaceB allele

<220>
<221> misc_feature
<222> (614)..(676)
<223> technical DNA /residues of polylinker sequence

<220>
<221> misc_feature
<222> (677)..(1435)
<223> 3' region of the deltaaceB allele

<220>
<221> misc_feature
<222> (1433)..(1435)
<223> stop codon of the deltaaceB allele

<400> 8
atgactgaac aggcaacaac aaccgatgaa ctggctttca caaggccgta tggcgagcag 60

gagaagcaaa ttcttactgc cgaagcggta caatttctga ctgagctggt gacgcatttt 120

[illegible] 141

ggaacgttgc ctgattttat ttcggaaaca gcttccattc gcgatgctga ttggaaaatt 240
cgcgggattc ctgcggactt agaagaccgc cgcgtagaga taactggccc ggtagagcgc 300
aagatggtga tcaacgcgct caacgccaat gtgaaagtct ttatggccga tttcgaagat 360
tcactggcac cagactggaa caaagtgatc gacgggcaaa ttaacctgcg tgatgcggtt 420
aacggcacca tcagttacac caatgaagca ggcaaaattt accagctcaa gcccaatcca 480
gcggttttga tttgtcgggt acgcggtctg cacttgccgg aaaaacatgt cacctggcgt 540
ggtgaggcaa tccccggcag cctgtttgat tttgcgctct atttcttcca caactatcag 600
gcactgttgg caaaagccga attccagcac actggcggcc gttactagtg gatccgagat 660
ctgcagaatt cggcttatgc ttactcacgc ctgttgatta aaacctgcca taaacgcggt 720
gcttttgcga tgggcggcat ggcggcgttt attccgagca aagatgaaga gcacaataac 780
caggtgctca acaaagtaaa agcggataaa tcgctggaag ccaataacgg tcacgatggc 840
acatggatcg ctcacccagg ccttgcggac acggcaatgg cggtattcaa cgacattctc 900
ggctcccgta aaaatcagct tgaagtgatg cgcgaacaag acgcgccgat tactgccgat 960
cagctgctgg caccttgtga tggtgaacgc accgaagaag gtatgcgcgc caacattcgc 1020
gtggctgtgc agtacatcga agcgtggatc tctggcaacg gctgtgtgcc gatttatggc 1080
ctgatggaag atgcggcgac ggctgaaatt tcccgtacct cgatctggca gtggatccat 1140
catcaaaaaa cgttgagcaa tggcaaaccg gtgaccaaag ccttgttccg ccagatgctg 1200
ggcgaagaga tgaaagtcat tgccagcgaa ctgggcgaag aacgtttctc ccaggggcgt 1260
tttgacgatg ccgcacgctt gatggaacag atcaccactt ccgatgagtt aattgatttc 1320
ctgaccctgc caggctaccg cctgttagcg taa 1353

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
30 January 2003 (30.01.2003)

PCT

(10) International Publication Number
WO 03/008604 A3

(51) International Patent Classification[7]: C12P 13/06, 13/08, 13/10, 13/12, 13/14, 13/20, 13/22, 13/24

(21) International Application Number: PCT/EP02/07352

(22) International Filing Date: 3 July 2002 (03.07.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

101 35 051.1	18 July 2001 (18.07.2001)	DE
60/306,867	23 July 2001 (23.07.2001)	US

(71) Applicant *(for all designated States except US)*: DEGUSSA AG [DE/DE]; Bennigsenplatz 1, 40474 Düsseldorf (DE).

(72) Inventor; and

(75) Inventor/Applicant *(for US only)*: HERMANN, Thomas [DE/DE]; Zirkonstrasse 8, 33739 Bielefeld (DE).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

— *of inventorship (Rule 4.17(iv)) for US only*

Published:

— *with international search report*

[Continued on next page]

(54) Title: PROCESS FOR THE PREPARATION OF L-AMINO ACIDS USING STRAINS OF THE ENTEROBACTERIACEAE FAMILY WHICH CONTAIN AN ATTENUATED ACEB GENE



(57) Abstract: The invention relates to a process for the preparation of L-amino acids, in particular L-threonine, in which the following steps are carried out: a) fermentation of microorganisms of the Enterobacteriaceae family which produce the desired L-amino acid and in which the aceB gene, or the nucleotide sequence which codes for this, is attenuated, in particular eliminated, b) concentration of the L-amino acid in the medium or in the cells of the bacteria, and c) isolation of the L-amino acid.

WO 03/008604 A3

(88) Date of publication of the international search report:
4 December 2003

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 02/07352

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C12P13/06 C12P13/08 C12P13/10 C12P13/12 C12P13/14
C12P13/20 C12P13/22 C12P13/24

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C12P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)
EPO-Internal, WPI Data, PAJ, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 5 378 616 A (TUJIMOTO NOBUHARU ET AL) 3 January 1995 (1995-01-03) page 2, column 2, paragraph 2	1-7
A	WO 94 28154 A (NUTRASWEET CO) 8 December 1994 (1994-12-08) page 1, line 10 - line 14; table 2	1-7
A	CHUNG T ET AL: "Glyoxylate bypass operon of Escherichia coli: cloning and determination of the functional map." JOURNAL OF BACTERIOLOGY. US, vol. 170, no. 1, January 1988 (1988-01), pages 386-392, XP008015355 ISSN: 0021-9193 the whole document	1-7

-/--

[X] Further documents are listed in the continuation of box C.

[X] Patent family members are listed in annex.

° Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
3 April 2003	17/04/2003

Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL – 2280 HV Rijswijk Tel. (+31–70) 340–2040, Tx. 31 651 epo nl, Fax: (+31–70) 340–3016	Kools, P

Form PCT/ISA/210 (second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 02/07352

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication,where appropriate, of the relevant passages	Relevant to claim No.
A	US 4 347 318 A (MIWA KIYOSHI ET AL) 31 August 1982 (1982-08-31) the whole document	1-7
A	REINSCHEID D J ET AL: "Malate synthase from Corynebacterium glutamaticum: sequence analysis of the gene and biochemical characterization of the enzyme" MICROBIOLOGY, vol. 140, no. 11, 1994, pages 3099-3108, XP008012735 Reading, GB ISSN: 1350-0872 the whole document	1-7
A	LANDGRAF J R ET AL: "THE ROLE OF H-NS IN ONE CARBON METABOLISM" BIOCHIMIE, MASSON, PARIS, FR, vol. 76, no. 10/11, 1994, pages 1063-1070, XP008014239 ISSN: 0300-9084 the whole document	6
A	RAE J L ET AL: "Sequences and expression of pyruvate dehydrogenase genes from Pseudomonas aeruginosa." JOURNAL OF BACTERIOLOGY, vol. 179, no. 11, June 1997 (1997-06), pages 3561-3571, XP002237063 US ISSN: 0021-9193 abstract	1-7
E	WO 03 008600 A (DEGUSSA ;HERMANN THOMAS (DE)) 30 January 2003 (2003-01-30) claim 7	7
E	WO 03 008602 A (DEGUSSA ;HERMANN THOMAS (DE)) 30 January 2003 (2003-01-30) claim 7	7
E	WO 03 008603 A (DEGUSSA ;HERMANN THOMAS (DE)) 30 January 2003 (2003-01-30) claim 7	7
E	WO 03 008616 A (DEGUSSA ;HERMANN THOMAS (DE)) 30 January 2003 (2003-01-30) claim 7	7

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/EP 02/07352

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5378616 A	03-01-1995	BR 9203053 A	30-03-1993
		FR 2680178 A1	12-02-1993
		JP 3106714 B2	06-11-2000
		JP 5244970 A	24-09-1993
		PH 30131 A	21-01-1997
		US 5393671 A	28-02-1995
WO 9428154 A	08-12-1994	AU 6960894 A	20-12-1994
		CA 2140527 A1	08-12-1994
		EP 0660875 A1	05-07-1995
		JP 7509375 T	19-10-1995
		WO 9428154 A1	08-12-1994
US 4347318 A	31-08-1982	JP 1029559 B	12-06-1989
		JP 1552063 C	23-03-1990
		JP 55131397 A	13-10-1980
		DE 3012921 A1	23-10-1980
		FR 2453216 A1	31-10-1980
		GB 2049670 A ,B	31-12-1980
WO 03008600 A	30-01-2003	DE 10135051 A1	06-02-2003
		WO 03008600 A2	30-01-2003
		WO 03008602 A2	30-01-2003
		WO 03008603 A2	30-01-2003
		WO 03008604 A2	30-01-2003
		WO 03008616 A2	30-01-2003
WO 03008602 A	30-01-2003	DE 10135051 A1	06-02-2003
		WO 03008600 A2	30-01-2003
		WO 03008602 A2	30-01-2003
		WO 03008603 A2	30-01-2003
		WO 03008604 A2	30-01-2003
		WO 03008616 A2	30-01-2003
WO 03008603 A	30-01-2003	DE 10135051 A1	06-02-2003
		WO 03008600 A2	30-01-2003
		WO 03008602 A2	30-01-2003
		WO 03008603 A2	30-01-2003
		WO 03008604 A2	30-01-2003
		WO 03008616 A2	30-01-2003
WO 03008616 A	30-01-2003	DE 10135051 A1	06-02-2003
		WO 03008600 A2	30-01-2003
		WO 03008602 A2	30-01-2003
		WO 03008603 A2	30-01-2003
		WO 03008604 A2	30-01-2003
		WO 03008616 A2	30-01-2003